1. Home
  2. Analysis
  3. Pentasa
  4. Amitiza

Pentasa and Amitiza drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pentasa (mesalamine) and Amitiza (lubiprostone). Common drug interactions include hepatic enzyme increased among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Pentasa and Amitiza. It is created by eHealthMe based on reports of 40 people who take the same drugs from the FDA, and is updated regularly.

What is Pentasa?

Pentasa has active ingredients of mesalamine. It is often used in crohn's disease. eHealthMe is studying from 23,325 Pentasa users. Check the latest studies of Pentasa.

What is Amitiza?

Amitiza has active ingredients of lubiprostone. It is often used in constipation. eHealthMe is studying from 10,567 Amitiza users. Check the latest studies of Amitiza.

On Jul, 12, 2026

40 people who take Pentasa and Amitiza together, and have interactions are studied.

Pentasa and Amitiza drug interactions.

What are the common drug interactions of Pentasa and Amitiza, by gender? *:

female:

  1. Hepatic enzyme increased
  2. Influenza
  3. Pneumonia
  4. Hypersensitivity
  5. Infusion site swelling
  6. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  7. Dizziness
  8. Nausea (feeling of having an urge to vomit)
  9. Chronic kidney disease
  10. Ear infection

male:

  1. Drug ineffective
  2. Decreased appetite
  3. Dehydration (dryness resulting from the removal of water)
  4. Grand mal convulsion (a type of generalized seizure that affects the entire brain)
  5. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  6. Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults)
  7. Malignant neoplasm progression (cancer tumour came back)
  8. Nausea (feeling of having an urge to vomit)
  9. Overdose

What are the common drug interactions of Pentasa and Amitiza, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Headache (pain in head)
  2. Pyrexia (fever)
  3. Abdominal pain
  4. Anorectal infection
  5. Anxiety
  6. Asthma
  7. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  8. Chills (felling of cold)
  9. Depression
  10. Dyspepsia (indigestion)

30-39:

  1. Calculus ureteric (stone in ureter)
  2. Injection site bruising
  3. Injection site pain
  4. Injection site vesicles (fluid- or air-filled cavity or sac at injection site)

40-49:

  1. Chronic kidney disease
  2. Ear infection
  3. Infusion site erythema (reddening of the skin at infusion site)
  4. Infusion site swelling
  5. Malaise (a feeling of general discomfort or uneasiness)
  6. Multiple allergies (allergy to multiple agents)
  7. Sinusitis (inflammation of sinus)
  8. Hepatic enzyme increased
  9. Influenza
  10. Pneumonia

50-59:

  1. Drug ineffective
  2. Hypersensitivity
  3. Lip swelling
  4. Oral mucosal blistering (mouth ulcer)
  5. Swelling face
  6. Swollen tongue (swelling of tongue)
  7. Anal fissure
  8. Angina unstable (chest pain due to ischemia of the heart muscle- unstable)
  9. Blindness
  10. Blood creatine phosphokinase increased

60+:

  1. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  2. Anal haemorrhage
  3. Limb injury
  4. Loss of consciousness
  5. Malignant neoplasm progression (cancer tumour came back)
  6. Nausea (feeling of having an urge to vomit)
  7. Vertigo
  8. Decreased appetite
  9. Dehydration (dryness resulting from the removal of water)
  10. Dizziness

What are the existing conditions these people have? *

  1. Depression: 6 people, 15.00%
  2. Pain: 6 people, 15.00%
  3. Immunodeficiency Common Variable: 6 people, 15.00%
  4. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 4 people, 10.00%
  5. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 4 people, 10.00%
  6. Stress And Anxiety: 4 people, 10.00%
  7. Sleep Disorder: 4 people, 10.00%
  8. Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 4 people, 10.00%
  9. Migraine (headache): 3 people, 7.50%
  10. Laxative Supportive Care: 3 people, 7.50%

* Approximation only. Some reports may have incomplete information.

Do you take Pentasa and Amitiza?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Pentasa and Amitiza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Pentasa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Amitiza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pentasa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Amitiza and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on mesalamine and lubiprostone (the active ingredients of Pentasa and Amitiza, respectively), and Pentasa and Amitiza (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.